Journal
EXPERT OPINION ON THERAPEUTIC TARGETS
Volume 11, Issue 7, Pages 891-897Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14728222.11.7.891
Keywords
ACVI; analgesia; conotoxin; neuropathic pain; RgIA; VCI.I
Categories
Funding
- NIGMS NIH HHS [P01 GM048677-160012, P01 GM048677] Funding Source: Medline
- NIMH NIH HHS [R01 MH053631-12, MH 53637, R01 MH053631] Funding Source: Medline
- NINDS NIH HHS [NS048158] Funding Source: Medline
Ask authors/readers for more resources
The alpha(9)alpha(10) nicotinic acetylcholine receptors (nAChRs) are recognized for their function in the hair cells of the inner ear; transcripts for alpha(9) and/or alpha(10) subunits have also been identified in a diverse range of other tissues, including immune cells. The functioning of alpha(9)alpha(10) nAChRs in these latter tissues is unknown. However, a recent series of studies has provided evidence that blockade of the alpha(9)alpha(10) nAChR can alleviate chronic pain resulting from overt peripheral nerve injury or inflammation and increase the functional recovery of damaged neurons. Systemic administration of alpha(9)alpha(10) antagonists produces an acute analgesia; repeated daily administrations produces sustained and cumulative levels of analgesia across 7 days without the development of tolerance. Although the exact mechanism of action is unknown, antagonism of the alpha(9)alpha(10) nAChRs reduces the number of immune cells present at the site of injury.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available